Source:http://linkedlifedata.com/resource/pubmed/id/12648069
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2003-3-21
|
| pubmed:abstractText |
Real-time quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) is increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral blood BCR-ABL/ABL ratio, as assessed by Q-RT-PCR, has been shown to correlate with the contemporary cytogenetic response in patients receiving imatinib (Glivec, Gleevec). We have used Q-RT-PCR to monitor the early molecular response to 4 weeks and 3 months of imatinib therapy, in 47 patients with established CML. After 4 weeks of imatinib therapy, patients whose BCR-ABL/ABL ratio had fallen to less than 50% that of baseline had a significantly higher probability of achieving a major cytogenetic response after 6 months of therapy, when compared with those whose ratio did not fall by this amount (P < 0.001). Similarly, patients whose ratio at 3 months was less than 10% of that at baseline had a significantly higher probability of achieving a major cytogenetic remission at 6 months (P < 0.001). Patients who achieved these falls in their BCR-ABL/ABL ratio at either 4 weeks or 3 months had a superior progression-free survival at a median follow-up of 16.5 months (P = 0.01 and 0.003 respectively). These effects were independent of patient age and disease stage. The occurrence of peripheral blood cytopenias sufficiently severe to interrupt therapy was unrelated to progression-free survival. In conclusion, the data suggest that the early trend in the BCR-ABL/ABL ratio may be clinically useful for the early identification of patients destined to fare poorly on imatinib.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Genetic Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0007-1048
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
120
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
990-9
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:12648069-Adult,
pubmed-meshheading:12648069-Aged,
pubmed-meshheading:12648069-Aged, 80 and over,
pubmed-meshheading:12648069-Antineoplastic Agents,
pubmed-meshheading:12648069-Disease-Free Survival,
pubmed-meshheading:12648069-Female,
pubmed-meshheading:12648069-Follow-Up Studies,
pubmed-meshheading:12648069-Fusion Proteins, bcr-abl,
pubmed-meshheading:12648069-Genetic Markers,
pubmed-meshheading:12648069-Humans,
pubmed-meshheading:12648069-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:12648069-Male,
pubmed-meshheading:12648069-Middle Aged,
pubmed-meshheading:12648069-Piperazines,
pubmed-meshheading:12648069-Proto-Oncogene Proteins c-abl,
pubmed-meshheading:12648069-Pyrimidines,
pubmed-meshheading:12648069-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:12648069-Treatment Outcome
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
|
| pubmed:affiliation |
Department of Haematology, Royal Liverpool University Hospital, UK.
|
| pubmed:publicationType |
Journal Article
|